The range of available GLP-1 medications differs significantly between online platforms and traditional endocrinologists, affecting both treatment options and costs for patients
The study is important because it confirms that GLP-1RA therapy has clinically meaningful systemic effects, reinforcing the need to understand how metabolic benefit is integrated with broader nutritional and physiological adaptation
Clients want precise, science-backed treatments and the market is growing
Eli Lilly reported these results in mid-2025, and the retatrutide availability timeline now points toward potential FDA approval no earlier than 2027, as additional phase 3 trials continue
Hepatology Communications , vol
They are successfully used for the treatment of childhood epilepsies, where several controlled clinical trials have now shown efficacy (Martin et al., 2016) and there is also some efficacy against seizures in adults